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Abstract
Background The Psoriasis Symptom Inventory (PSI) is a patient-reported outcome measure designed to assess psoriasis 
signs and symptoms.
Objectives The aim was to assess the usefulness of the PSI in enhancing patient care in the clinical setting.
Methods Eight dermatology clinics in six countries enrolled adults representing the full spectrum of psoriasis severity who 
regularly received care at the clinic. Patients were administered the eight-item PSI (score range 0–32; higher scores indicate 
greater severity) while waiting for the physician; the physician conducted a static physician global assessment (sPGA) and 
estimated psoriasis-affected body surface area (BSA) at the same visit. Physicians completed a brief questionnaire after each 
patient visit, and were interviewed about the PSI after all patients were seen.
Results The clinics enrolled 278 patients; mean [standard deviation (SD)] psoriasis-affected BSA was 7.6% (11.4). Based 
on BSA, 47.8% had mild psoriasis, 29.1% had moderate psoriasis, and 23.0% had severe psoriasis. Based on sPGA, 18.7% 
were clear/almost clear, 67.3% were mild/moderate, and 14.0% were severe/very severe. The mean (SD) PSI total score was 
12.2 (8.3). Physicians spent a mean (SD) 4.9 (4.8) min discussing PSI findings with their patients (range 0–20 min). Key 
benefits of PSI discussions included the following: new information regarding symptom location and severity for physicians; 
prompting of quality-of-life discussions; better understanding of patient treatment priorities; change in treatment regimens 
to target specific symptoms or areas; and improvement of patient–physician relationship.
Conclusions The PSI was useful for treated and untreated patients to enhance patient–physician communication, and influ-
enced treatment decisions.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4025 7-019-00458 -2) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Psoriasis is a chronic, immune-mediated, hyperproliferative 
skin disease characterized by erythematous, scaly plaques 
[1]. Globally, an estimated 100–125 million people suffer 
from psoriasis [2, 3]. This disease has significant negative 
impacts on health-related quality of life, most notably on 
emotional and social domains [4–6]. In a recent National 
Psoriasis Foundation survey of 5604 patients with psoria-
sis, 94% reported that psoriasis was a significant problem 
in daily life [5]. More than 80% reported feelings of self-
consciousness, anger or frustration, helplessness, and embar-
rassment due to psoriasis [5]. Understanding the impact of 
psoriasis and the patient’s perception of psoriasis is impor-
tant for developing a patient-centered approach to psoriasis 
treatment.
The Psoriasis Symptom Inventory (PSI) is a patient-
reported outcome (PRO) measure that was designed to 
assess the patient’s perception of psoriasis signs and 
symptoms [7]. The PSI is an eight-item questionnaire that 
assesses signs and symptoms of itch, redness, scaling, burn-
ing, stinging, cracking, flaking, and pain. The severity of 
each item/sign or symptom is scored on a scale of 0 (“not at 
all”) to 4 (“very severe”); the eight items are summed for a 
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Key Points 
The Psoriasis Symptom Inventory (PSI) is a validated 
patient-reported outcome instrument that was designed 
to quantify the patient’s perception of psoriasis signs and 
symptoms.
Use of the PSI in real-world dermatology clinics elicited 
meaningful discussions of psoriasis signs and symptoms 
between physicians and patients (treated and untreated 
and across a wide range of disease severity), improved 
patient perception of the treating physician, and influ-
enced treatment decisions.
The PSI is a validated assessment tool that allows stand-
ardized objective evaluation of a patient’s perception of 
psoriasis signs and symptoms, and importantly, improves 
disease-specific communications between physician and 
patient.
global clinical practice sites were selected by the IPC to 
participate in the study, including three sites in the USA 
(Farmington, CT; St. Louis, MO; and Salt Lake City, UT) 
and one site each in the UK (Manchester), the Netherlands 
(Nijmegen), Brazil (Porto Alegre), Chile (Santiago), and 
Canada (Quebec City). Study sites regularly treated patients 
with mild to severe psoriasis. All study sites obtained insti-
tutional review board (IRB) approval. All patients provided 
written informed consent prior to initiation of study-specific 
procedures.
At a regularly scheduled clinic visit, potentially eligible 
patients were identified and contacted by clinic staff, com-
pleted screening and enrollment, and were administered the 
paper 7-day recall version of the PSI. Patients were also 
asked about how much they were currently bothered by pso-
riasis symptoms, the severity of their current symptoms, the 
worst severity of their symptoms ever and before treatment, 
and the location(s) and severity of current psoriasis lesions. 
During the visit, the physician documented the patient’s 
psoriasis-affected body surface area (BSA) and static phy-
sician global assessment (sPGA) score [14], and used the 
patient’s information on the PSI to support discussions about 
the patient’s psoriasis signs and symptoms. After the visit, 
the physician completed a one-page survey about the visit. 
After enrollment was closed at each site (upon enrollment 
of ~ 35 patients), the participating physicians completed a 
20–30-min qualitative telephone interview.
2.2  Patients
To be eligible, patients were adults (≥ 18 years of age), had 
physician-confirmed diagnosis of mild to severe plaque pso-
riasis, and were able to complete the PSI and discuss their 
symptoms with their physician. Patients who had any clini-
cally relevant condition, were receiving treatment that could 
interfere with the patient’s ability to focus their responses 
on psoriasis symptoms, or were enrolled in a psoriasis 
investigational drug study were excluded. Enrollment was 
monitored to assure a distribution of ~ 40% mild psoria-
sis (affected BSA 0–4%), ~ 40% moderate psoriasis (BSA 
5–9%), and ~ 20% severe psoriasis (BSA ≥ 10%), and that 
~ 50% of the population was treatment naïve as well as bal-
anced for demographic characteristics of sex and age.
2.3  Study Outcomes
The primary outcome was the physician experiences on 
the usefulness of the PSI based on physician surveys and 
interviews. The physician survey included questions about 
the length of time spent discussing the PSI, if other psoria-
sis symptoms were discussed, if any new information was 
obtained from the discussion, if the PSI data enhanced the 
discussion or interaction with the patient, any benefits that 
total score (range 0–32). The PSI is valid, reproducible, and 
responsive to change [8, 9], and can demonstrate improve-
ments in symptoms with treatment [10]. Two versions with 
different recall periods were developed and validated: a 24-h 
recall period and a 7-day recall period [8, 11]. The PSI has 
undergone cultural/linguistic validation with a wide variety 
of languages using standard PRO translation methodology 
(including all languages used in this study) [12, 13].
In a previous study, it was demonstrated that PSI scores 
were responsive to clinical changes as assessed by the Pso-
riasis Area and Severity Index (PASI); therefore, PSI score 
may be useful in monitoring psoriasis severity in the clinic 
[9]. In a partnership between the International Psoriasis 
Council (IPC) and Amgen (the developer of the PSI), we 
tested the utility of the PSI in eight dermatology clinics in 
six countries that treat and manage patients with psoriasis. 
In addition to administering the PSI to their regular patients, 
the physicians at the clinics also filled out a brief question-
naire on each patient interaction, and were subsequently 
interviewed to discuss their impressions on the use of the 
PSI. The objective of the study was to assess the usefulness 
of the PSI in enhancing patient care in the clinical setting.
2  Patients and Methods
2.1  Study Design
This was a noninterventional, international, multicenter, 
cross-sectional study of the clinical usefulness of physicians’ 
use of the PSI with their patients with plaque psoriasis. Eight 
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the PSI provided toward patient care, and if the PSI was 
useful to have during the visit. The qualitative interview 
was based on a structured interview guide, which used open-
ended, exploratory questions by trained interviewers. Physi-
cian interviews were audio recorded, transcribed, and sum-
marized. The transcripts were used to extract key quotations 
and summary statements against specific questions discussed 
during the interview process.
3  Results
3.1  Patients
Across the eight study sites, 278 patients were enrolled in 
the study. The mean [standard deviation (SD)] age was 47.5 
(14.0) years; 57.9% of the patients were male (Table 1). 
Additional demographic information is shown in Supple-
mental Table S1. Based on affected BSA, 47.8% of patients 
had mild psoriasis (range 40.0–67.5% across all sites), 29.1% 
had moderate psoriasis (range 12.5–40.0%), and 23.0% had 
severe psoriasis (range 17.5–42.9%). Across all patients, 
18.7% had an sPGA score 0–1 (clear–almost clear) (range 
2.9–28.6% across all sites), 67.3% had an sPGA score 2–3 
(mild–moderate) (range 42.9–91.4%), and 14.0% had an 
sPGA score 4–5 (severe–very severe) (range 0–37.1%). 
Forty-nine patients (17.6%) were treatment-naïve or receiv-
ing no treatment for their psoriasis.
The mean (SD) PSI total score for all patients was 12.2 
(8.3). Mean PSI item scores differed by study site, but all 
were within the range of SDs from the US validation study 
(Fig. 1) [8]. PSI total scores also differed by study site 
(range 10.3–14.9); study sites with a greater percentage of 
patients who had severe disease reported higher mean PSI 
total scores. The mean (SD) PSI total scores by study site 
were 12.6 (8.4) for CT, USA; 10.6 (7.9) for MO, USA; 13.3 
(8.8) for UT, USA; 11.7 (9.2) for the UK; 10.5 (7.5) for the 
Netherlands; 14.9 (8.1) for Brazil; 12.9 (9.1) for Chile; and 
10.3 (6.8) for Canada. Based on PSI total score categories, 
107 patients (38.5%) had no/mild symptoms (PSI total score 
0–8), 89 (32.0%) had moderate symptoms (PSI total score 
9–16), 57 (20.5%) had severe symptoms (PSI total score 
17–24), and 25 (9.0%) had very severe symptoms (PSI total 
score 25–32).
3.2  Physician Surveys
The PSI was considered to be a useful tool during the clinic 
visit for three-quarters of the participating patients. Overall, 
physicians spent a mean (SD) of 4.9 (4.8) min discussing 
the PSI with their patients (range 0–20 min). The amount of 
time spent discussing the PSI varied based on PSI total score 
category (none/mild, moderate, severe, and very severe) 
and treatment status (treated and treatment naïve). The 
mean (SD) time for treated patients was 3.4 (3.8) min for 
patients with none/mild symptoms, 5.1 (4.4) min for patients 
with moderate symptoms, 5.8 (6.6) min for patients with 
severe symptoms, and 6.7 (5.5) min for patients with very 
severe symptoms. The mean (SD) time for treatment-naïve 
patients was 6.1 (5.1) min for patients with none/mild symp-
toms, 4.5 (4.6) min for patients with moderate symptoms, 
4.9 (4.7) min for patients with severe symptoms, and 7.8 
(7.3) min for patients with very severe symptoms.
In the surveys, physicians noted that symptoms not usu-
ally discussed in routine visits were discussed in the context 
of the PSI, and patients were encouraged to discuss new 
information (Table 2). In some cases, physicians noted that 
the use of the PSI appeared to improve the patient–physician 
relationship.
3.3  Physician Interviews
In qualitative interviews, all eight physicians endorsed the 
PSI as an aid in patient–physician interactions regarding 
psoriasis disease management (Table 3). The PSI was deter-
mined to be useful for many reasons. There was a low time 
burden (less than 5 min) to discuss the information. The 
physicians obtained a better understanding of the patient-
specific experiences related to psoriasis and often re-exam-
ined patient priorities for treatment. Over time, the PSI could 
be used to document progress in treatment satisfaction. The 
physicians also noted several benefits for patients with the 
use of the PSI. The instrument provided the patients with 
the ability to rate their symptoms in writing (which puts 
less pressure on the patient), the symptoms were provided 
in the instrument, and patients were less likely to underre-
port symptoms in the time-sensitive context of a clinic visit. 
Patients were able to address sensitive issues such as geni-
tal symptoms. Patients also discussed quality-of-life aspects 
as they related to their psoriasis signs and symptoms, and 
some patients were able to use PSI symptom ratings to alert 
the physician to their distress from their psoriasis signs and 
symptoms when they had been previously unable to do so 
verbally. Physicians, who generally focused on lesion size, 
were frequently directed to a specific lesion location when a 
sign or symptom was rated as severe by the patient. The PSI 
appeared to be particularly useful in driving communication 
with patients with low verbal aptitude. Physicians noted that 
the PSI discussions affected some treatment decisions. For 
example, one physician added topical therapy for specific 
lesions in patients who were receiving biologic therapies, 
and one physician opted for more aggressive regimens when 
the PSI score was high in patients with low affected BSA.
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4  Discussion
In this study of the use of the PSI in the setting of routine 
clinical practice, we made three key observations. First, 
physicians received new information about their patients’ 
perceptions of psoriasis symptoms. For example, patients 
who appeared to the physician to have mild disease overall 
sometimes rated specific symptoms as very severe or noted 
symptoms in problem areas. Second, the PSI information 
helped with making decisions about care. In some instances, 
topical therapies were added to problem areas, and in some 
instances, systemic therapy was initiated. Third, the burden 
of the instrument was low for the patient and for the physi-
cian. Patients completed the instrument while waiting to see 
the physician, and the physicians required only 5 min on 
average during the visit to review the results.
Physicians and patients use different measures to esti-
mate psoriasis severity in both clinical trials and in clinical 
practice. In psoriasis clinical trials, the PASI is the most 
commonly used measure of psoriasis severity and the Der-
matology Life Quality Index (DLQI) is the most common 
measure of patient-reported health-related quality of life 
[15]. In clinical practice, physicians focus on elements of the 
PASI (e.g., size and appearance of lesions), whereas patients 
tend to focus on the location of lesions and impact of the dis-
ease on their lives. The correlation between improvements in 
psoriasis lesions (as measured by PASI) and improvements 
in quality of life (as measured by DLQI) varies, with some 
studies showing weak correlations [16, 17].
A recent study of patients enrolled in the Swedish pso-
riasis registry (PsoReg) showed that the decision to initi-
ate systemic therapy was more strongly associated with the 
patient’s PASI score than with DLQI results [18]. While this Ta
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Fig. 1  Mean PSI item scores by study site. Mean item scores are 
shown for study sites in Brazil (yellow), Canada (green), Chile (red), 
the Netherlands (gray), the UK (orange), the US sites (data from 3 
sites pooled; blue), and the US study used to validate the PSI [8] 
(bold hashed line). Upper and lower dashed lines represent SDs for 
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approach is appropriate for most patients, patients with a low 
affected BSA who rated their disease as moderate to severe 
(~ 30% of patients in a recent survey [19]) represent a patient 
population that is likely to be undertreated. Patients with a 
single severe symptom (such as itch [20, 21]) or with lesions 
in certain areas (such as visible areas [22]) may report poor 
quality of life and yet have a low PASI score. A recent survey 
of dermatologists showed that the level of treatment satisfac-
tion for approximately one in five patients was misaligned 
with the physician’s level of satisfaction with treatment [23]. 
These patients reported a poorer quality of life and more 
severe symptoms than the patients who were aligned with 
their physicians. Patients are reliable in the assessment of 
their disease severity [19, 24, 25]. These observations sup-
port a growing call for better communication between phy-
sicians and patients to achieve optimal treatment regimens, 
which improve quality of life [6, 26–28]. In particular, it has 
been suggested that physicians need to carefully evaluate the 
impacts of signs and symptoms on patients [19].
Differences in PSI item and total scores were noted 
between geographic regions, although statistically all values 
were within the SDs for item and total scores recorded in the 
validation study. For five of the eight PSI item scores, Latin 
American sites (Brazil and Chile) had the highest mean 
scores, which may reveal a significant cultural difference. 
While we do not know the specific reasons for these differ-
ences, ethnic and racial differences may potentially impact 
the perception and effects of psoriasis symptoms. Addition-
ally, quality of life and standards of living vary geographi-
cally, which may impact perception of disease severity based 
on the geographic location of the patient. Cultural and geo-
graphic differences in the patient–physician relationship may 
also exist, and the PSI could potentially normalize these dif-
ferences cross-culturally. Further studies in larger real-world 
populations are needed to understand these differences.
Differences were also seen in the time spent discussing 
the PSI based on PSI total scores. In both treated and treat-
ment-naïve patients, the time spent discussing the PSI was 
longer in patients who had rated their symptoms as more 
severe on the PSI compared to patients with no/mild symp-
toms. Physicians may therefore consider the PSI score as an 
indication of the amount of time that may be required for a 
particular patient visit. Overall, the investigators responded 
that patients with severe psoriasis required more time dur-
ing the clinical evaluation to discuss symptom scores. For 
example, among the treated group, a mean (SD) of 5.8 
(6.6) min was spent on patients with severe symptoms, and 
among the treatment-naïve group, 4.9 (4.7) min was spent 
on patients with severe symptoms, and 7.8 (7.3) min was 
spent on patients with very severe symptoms. Notably, for 
patients with high PSI scores, a higher proportion of physi-
cians noted that the PSI discussions assisted with decision 
on care and were useful to have during the visit (data not 
shown). The PSI may therefore be particularly useful for 
patients with severe/very severe disease.
There were some limitations to this study. Both the 
physicians and the patients were aware that the PSI was 
administered as part of a clinical survey, which could have 
introduced a bias towards favorable impressions of the 
instrument. The generalizability of the PSI usefulness may 
be restricted because the data were collected in referral cent-
ers focused on the treatment of psoriasis. An instrument that 
adds a 5-min discussion to a clinic visit could be construed 
as too burdensome for some physicians or patients. Some 
patients’ symptoms may be deliberately overestimated to 
increase the likelihood of obtaining systemic (primarily bio-
logic) treatments; this may be driven by access to health care 
in some countries. Psoriatic arthritis, a common comorbidity 
in patients with psoriasis, is not addressed in the PSI, which 
assesses skin symptoms but not joint symptoms. The study 
did not address conversations about psoriatic arthritis in the 
physician surveys or interviews. Finally, although the overall 
sample size was large, the sample sizes of individual regions 
were too small to allow regional comparisons.
A strength of the study was the relatively large patient 
population that was recruited across several countries. 
Patients represented a wide range of disease severity and 
treatments, and the population was reasonably balanced 
among treatment-naïve and treatment-experienced patients 
and across genders. The global distribution of study sites 
allows for external validity of the instrument. The use of 
the PSI provides opportunities for working in the virtual 
Table 2  Physician surveys to evaluate PSI usefulness in clinical practice
PSI Psoriasis Symptom Inventory
Physician 
response of yes, 
n (%)
Symptoms that were not usually covered in routine visits were discussed 94 (33.8)
Physicians found that patients were encouraged to bring forward new information for discussion 157 (56.5)
The new information was helpful in making better decisions about each patient’s care 185 (66.5)
Overall, the use of the PSI was helpful during the patient visit 209 (75.2)
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Table 3  Select quotes from physician interviews
Interview topic Select quotes
What was your overall experience with the PSI 
in this study?
“It just helped to direct consultations, fairly rapidly, to problem areas, and the main observation 
was, patients who I’ve been seeing for many, many years, actually aren’t necessarily volun-
teering these things…”
“[A]llowed the treating practitioner to understand the effect of the disease state symptomatically 
on the patient. That went beyond what we could necessarily glean from our typical approaches 
to seeing patients with psoriasis.”
Were there changes in how patients understood 
or discussed the severity of their psoriasis?
“Sometimes the patient really doesn’t want to speak about their disease, or the appearance, and 
when they are feeling depression they can express something…they do not want to say…in 
their own mind they can do that in writing and they cannot do that in speaking.”
Were there changes in how you perceived the 
patient’s perception of the severity of their 
psoriasis?
“There were many times when the PSI outcome seemed very different from what I would 
expect.”
“I have no other way of knowing how severe their symptoms are if they don’t tell me and so it 
provided a more objective place to start…”
“[F]or some patients there…was far greater distress from symptoms than I was anticipating.”
What were some benefits of using the PSI dur-
ing your discussions with patients?
“[I]t’s nice to have a number to quantify their symptoms.”
“[O]n a more, sort of global level, I think was aware that many patients have a lot of distress 
from their psoriasis.”
“We clearly interact, now with the patient, and how the patient felt about their lesions.”
Describe any change in how the patients com-
municated with you.
“I think that it was really something that will help to improve the conversation and the relation 
between patient and doctor.”
“[W]e often will express itch but I think it was a validation of the fact that the psoriasis 
symptoms are more than just itch or pain, that it can be stated different ways, and I think they 
appreciated that…”
How did the patient’s understanding of sever-
ity compare to their diagnosis?
“[T]he severity indicated by the questionnaire, the ultimate score that I got back, was in disa-
greement…with the results of examination…the PSI outcome seemed very different from 
what I would expect.”
“[T]he patients are affected by, sometimes, the particular site, like forearms, or the hands, or the 
lesion on the neck, where it appears more…found that it was worse from the patient’s point of 
view.”
Were there any surprises for you in discussing 
severity with patients?
“I wouldn’t say surprises but the burning symptom was brought up more than I thought.”
“Yes, I would say, at least, a third to half of patients that we enrolled I felt somewhat surprised 
by the discrepancy between what I thought they would have and what they actually had as a 
score on the PSI. First the total score could be surprising, let’s say I predicted they’d have a 12 
and they came back with a 23.”
“[I]f the patient might calmly state, yes, I experience itch, you might think, well, they’re not 
really emphasizing that symptom. But then…they score the itch domain in the PSI, they give 
it either a 3 or 4.”
Were there any problematic or beneficial 
trends that you noticed?
“Sometimes not with the bigger lesions, but where the lesions are, and it really affect patients.”
“Itching…that came out, the burning sensation…there were more patients talking about that 
than we expected.”
Did you notice any trends about symptoms that 
were most upsetting to patients?
“It affects their sleeping at night. It affects their relations with their partners…”
“[G]enital involvement psoriasis…”
“The burning sensation is something that, it’s not a rare thing, but it’s not that common.”
“Anything that shows up on the face is always on their mind.”
Overall, did the PSI represent what patients’ 
symptoms were like?
“[I]t was proof to me…the eight domains are highly relevant to the physical experience of hav-
ing psoriasis.”
Were the discussions about the PSI useful? “I think the net effect was positive, given the time required for the patient to complete the PSI 
was minimal, and the information gleaned from the results of the PSI was, on balance, very 
helpful.”
“This is a good representation of what the patient is now at the moment we speak.”
How did the PSI enhance patient care, if at all? “I think that it was an advantage specifically because it doesn’t take me so much longer and I 
can go deeper in the relation with the patient.”
“Yes, because many of the domains of the PSI are not commonly assessed in your average 
dermatology visit.”
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environment. Patient-reported severity is condensed to a 
single-digit assessment. Importantly, the instrument can be 
used to document a treatment response.
5  Conclusion
In conclusion, the PSI has the potential to improve derma-
tologic practice by providing a comprehensive tool to assess 
psoriasis symptoms. In this study, physicians endorsed the 
usefulness of the PSI to discuss symptoms and symptom 
impacts in routine clinic visits. The discussions informed 
treatment decisions and enhanced physician–patient rela-
tionships. Despite the greater amount of time spent discuss-
ing the PSI in patients with more severe disease, physicians 
treating those patients reported an influence of the PSI dis-
cussion on treatment decisions. The PSI may improve com-
munication between physicians and patients and provide an 
option for quality monitoring.
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Table 3  (continued)
Interview topic Select quotes
Were there changes to treatment plans based 
on the information in the PSI?
“For example, patients with low BSA score but…in the questionnaire…had an impact on their 
quality or life…I would go more aggressive in choosing a treatment.”
“It’s very useful to learn about the value of the Psoriasis Symptoms Index in the detecting the 
need for a change.”
“But, what I did find is that I did refine some of the topical measures that I was prescribing…
it tended to be site-specific issues for patients…the genital disease…or one highly pruritic 
patch…”
“I do think it has the ability to help drive a conversation to escalate or de-escalate therapy.”
Were there discussions about quality of life 
prompted by the PSI process itself?
“For introspective patients, patients that do not speak a lot, or don’t like to speak a lot or have 
very, very low self-esteem the questionnaire just brought up a lot of issues that we could not 
get from them in other ways.”
Did the discussions about PSI results bring to 
light any new information?
“[O]ne of my patients had very limited body surface area but her scores were so severe that it 
kind of surprised me…other people…had a lot of psoriasis but their scores were a little bit 
lower.”
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